Agenus Inc. (Nasdaq: AGEN) entered a global alliance with Incyte Corp. (Nasdaq:
INCY) to develop, license and commercialize immuno-therapeutics using
Agenus' proprietary Retrocyte Display antibody discovery platform. Shares of Agenus surged $1.10 to $5.21 while Incyte stock lost $1.14 to $72.07.
Agenus enters global alliance with Incyte
January 09, 2015 at 12:31 PM EST
